MedTrace Logo

Efficacy of Probiotics in Reducing Duration and Symptoms of COVID-19

NCT04621071 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2021-10-29

No results posted yet for this study

Summary

COVID-19 disease caused by a new coronavirus (SARS-CoV-2) has received worldwide attention. No specific antiviral treatment is recommended for COVID-19 and no vaccine is currently available. Probiotics may be considered as an option of treatment since they have anti-viral effect, trigger immunomodulation and have low side-effects.

This randomized controlled trial aims to evaluate the efficacy of probiotics to reduce the duration and symptoms of COVID-19 in a symptomatic population tested positive to SARS-CoV-2, self-caring at home.

Conditions

Interventions

DIETARY_SUPPLEMENT

Probiotics (2 strains 10x10^9 UFC)

Probiotic vs Placebo (1:1)

DIETARY_SUPPLEMENT

Placebo (potato starch and magnesium stearate)

Probiotic vs Placebo (1:1)

Sponsors & Collaborators

  • Lallemand Health Solutions

    collaborator INDUSTRY

  • Centre de recherche du Centre hospitalier universitaire de Sherbrooke

    lead OTHER

Principal Investigators

  • Jean-Charles Pasquier, Dr · CIUSSSE-CHUS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-12
Primary Completion
2021-08-19
Completion
2021-10-12

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04621071 on ClinicalTrials.gov